Transarterial Chemoembolization Treatment in the Management of BCLC C Stage Hepatocellular Carcinoma: A Large Real-World Observational Study of 885 Cases
Xin Yin,Bei Tang,Jia Yuan,Miao Li,Boheng Zhang,Yu-Hong Gan,Yan-hong Wang,Ning-lin Ge,Yi Chen,Rong-xin Chen,Li-Xin Li,Bi-Wei Yang,Lan Zhang,Tong-chun Xue,Zhenggang Ren
DOI: https://doi.org/10.1200/jco.2018.36.15_suppl.e16115
IF: 45.3
2018-01-01
Journal of Clinical Oncology
Abstract:e16115 Background: Patients with advanced stage hepatocellular carcinoma (HCC) have a dismal prognosis. The Barcelona Clinic Liver Cancer (BCLC) staging system does not recommend transarterial chemoembolization (TACE) for treating BCLC C HCC. However, numerous Asian-Pacific institutes still perform TACE for this patient group. There remains a paucity of large real-world data characterizing treatment outcomes of these patients.We aimed to share experiences of 885 cases of BCLC C stage HCC patients treated by TACE in real-world practice. Methods: 885 patients were included in this real-world study who received TACE based monotherapy or combination therapy in liver cancer institute, Fudan University between January 2008 and December 2015. We investigated the clinical outcomes of TACE-based treatment in BCLC C stage HCC. Results: In this cohort of 885 BCLC C HCC patients, vascular invasion was present in 582 patients (65.8%), lymph node involvement was present in 108 patients(12.2%), extrahepatic metastases was present in 232 patients (26.2%).The mean number of TACE per patient was 3.0±1.9 sessions. Median overall survival was 8.0 months (range 3-37) for the entire study population. Of all the patients, 600 patients received TACE-alone treatment, 137 patients received TACE combined Sorafenib treatment, 41 patients received TACE combined local regional treatment, 59 patients received TACE with chemotherapy, 123 patients received TACE with radiotherapy. The median survival time was 6.0 months for TACE-alone group, 11.5 months for TACE+Sorafenib group, 19.8 months for TACE+local regional treatment group, 12.0 month for TACE+chemotherapy group and 12.0 months for TACE+radiotherapy group respectively.These data showed that TACE-based combination therapy can improve overall survival in BCLC C stage HCC, in comparison with TACE alone treatment.After propensity score matching and adjusting for potential confounders, there were still significant survival differences between TACE-alone group and TACE-based combination treatments mentioned above. Conclusions: TACE-based combination therapy can improve overall survival in BCLC C stage HCC patients.